The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
Open accessAbstract
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. In this review, we provide background information on NY-ESO-1 expression and function in normal and cancerous tissues. Furthermore, NY-ESO-1-specific immune responses have been observed in various cancer types; however, their utility as biomarkers are not well determined. Finally, we describe the immune-based therapeutic options targeting NY-ESO-1 that are currently in clinical trial. We will highlight the recent advancements made in NY-ESO-1 cancer vaccines, adoptive T cell therapy, and combinatorial treatment with checkpoint inhibitors and will discuss the current trends for future NY-ESO-1 based immunotherapy. Cancer treatment has been revolutionized over the last few decades with immunotherapy emerging at the forefront. Immune-based interventions have shown promising results, providing a new treatment avenue for durable clinical responses in various cancer types. The majority of successful immunotherapy studies have been reported in liquid cancers, whereas these approaches have met many challenges in solid cancers. Effective immunotherapy in solid cancers is hampered by the complex, dynamic tumor microenvironment that modulates the extent and phenotype of the antitumor immune response. Furthermore, many solid tumor-associated antigens are not private but can be found in normal somatic tissues, resulting in minor to detrimental off-target toxicities. Therefore, there is an ongoing effort to identify tumor-specific antigens to target using various immune-based modalities. CTAs are considered good candidate targets for immunotherapy as they are characterized by a restricted expression in normal somatic tissues concomitant with a re-expression in solid epithelial cancers. Moreover, several CTAs have been found to induce a spontaneous immune response, NY-ESO-1 being the most immunogenic among the family members. Hence, this review will focus on NY-ESO-1 and discuss the past and current NY-ESO-1 targeted immunotherapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4
Qureshi, O. S., Zheng, Y., Nakamura, K., Attridge, K., Manzotti, C., Schmidt, E. M., Baker, J., Jeffery, L. E., Kaur, S., Briggs, Z., et al. (2011) · Science · doi:10.1126/science.1202947 · Cited by 1,860 · cited 1×
“In addition, CTLA-4 is constitutively expressed on regulatory T cells, which through competitive binding with B7 and/or induction of B7 internalization reduces the availability of B7 on antigenpresenting cells to form the CD28:B7 costimulatory signal for T cell activation and survival (123, 124).”
BackgroundRobbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,632
Cancer/testis antigens, gametogenesis and cancer
Simpson, A. J. G., Caballero, O. L., Jungbluth, A., Chen, Y.-T., & Old, L. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1669 · Cited by 1,582
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
Chen, Y.-T., Scanlan, M. J., Sahin, U., Türeci, Ö., Gure, A. O., Tsang, S., Williamson, B., Stockert, E., Pfreundschuh, M., & Old, L. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1914 · Cited by 1,247
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
Hunder, N. N., Wallen, H., Cao, J., Hendricks, D. W., Reilly, J. Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J. A., & Yee, C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800251 · Cited by 911
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003345107 · Cited by 859
Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A., Weiss, B., Finklestein, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3910 · Cited by 856
Robbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2708 · Cited by 807
Jäger, E., Chen, Y.-T., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jäger, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.2.265 · Cited by 725
A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens
Stockert, E., Jäger, E., Chen, Y.-T., Scanlan, M. J., Gout, I., Karbach, J., Arand, M., Knuth, A., & Old, L. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1349 · Cited by 698
Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650
Reversal of the TCR Stop Signal by CTLA-4
Schneider, H., Downey, J., Smith, A., Zinselmeyer, B. H., Rush, C., Brewer, J. M., Wei, B., Hogg, N., Garside, P., & Rudd, C. E. (2006) · Science · doi:10.1126/science.1131078 · Cited by 621
Cancer/testis (CT) antigens: Potential targets for immunotherapy
Caballero, O. L., & Chen, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01303.x · Cited by 554
Liakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806075105 · Cited by 549
Weber, J. S., Kudchadkar, R. R., Yu, B., Gallenstein, D., Horak, C. E., Inzunza, H. D., Zhao, X., Martinez, A. J., Wang, W., Gibney, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4802 · Cited by 535
Davis, I. D., Chen, W., Jackson, H., Parente, P., Shackleton, M., Hopkins, W., Chen, Q., Dimopoulos, N., Luke, T., Murphy, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403572101 · Cited by 440
CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens
Almeida, L. G., Sakabe, N. J., deOliveira, A. R., Silva, M. C. C., Mundstein, A. S., Cohen, T., Chen, Y.-T., Chua, R., Gurung, S., Gnjatic, S., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn673 · Cited by 433
Li, H., Chiappinelli, K. B., Guzzetta, A. A., Easwaran, H., Yen, R.-W. C., Vatapalli, R., Topper, M. J., Luo, J., Connolly, R. M., Azad, N. S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1782 · Cited by 430
Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
Jäger, E., Nagata, Y., Gnjatic, S., Wada, H., Stockert, E., Karbach, J., Dunbar, P. R., Lee, S. Y., Jungbluth, A., Jäger, D., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.9.4760 · Cited by 398
Autoreactive T Cells in Healthy Individuals
Danke, N. A., Koelle, D. M., Yee, C., Beheray, S., & Kwok, W. W. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.5967 · Cited by 377
The biology of cancer testis antigens: Putative function, regulation and therapeutic potential
Fratta, E., Coral, S., Covre, A., Parisi, G., Colizzi, F., Danielli, R., Marie Nicolay, H. J., Sigalotti, L., & Maio, M. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.02.001 · Cited by 375
Fourcade, J., Sun, Z., Pagliano, O., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Olive, D., Kuchroo, V., & Zarour, H. M. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2637 · Cited by 372
Dhodapkar, M. V., Sznol, M., Zhao, B., Wang, D., Carvajal, R. D., Keohan, M. L., Chuang, E., Sanborn, R. E., Lutzky, J., Powderly, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008068 · Cited by 365
Triggering TLR signaling in vaccination
van Duin, D., Medzhitov, R., & Shaw, A. C. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.005 · Cited by 364
Gure, A. O., Chua, R., Williamson, B., Gonen, M., Ferrera, C. A., Gnjatic, S., Ritter, G., Simpson, A. J. G., Chen, Y.-T., Old, L. J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1203 · Cited by 357
Yuan, J., Gnjatic, S., Li, H., Powel, S., Gallardo, H. F., Ritter, E., Ku, G. Y., Jungbluth, A. A., Segal, N. H., Rasalan, T. S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810114105 · Cited by 348
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
Jungbluth, A. A., Chen, Y.-T., Stockert, E., Busam, K. J., Kolb, D., Iversen, K., Coplan, K., Williamson, B., Altorki, N., & Old, L. J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1282 · Cited by 347
Yuan, J., Adamow, M., Ginsberg, B. A., Rasalan, T. S., Ritter, E., Gallardo, H. F., Xu, Y., Pogoriler, E., Terzulli, S. L., Kuk, D., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110814108 · Cited by 332
Oncogenic cancer/testis antigens: prime candidates for immunotherapy
Gjerstorff, M. F., Andersen, M. H., & Ditzel, H. J. (2015) · Oncotarget · doi:10.18632/oncotarget.4694 · Cited by 320
The MAGE proteins: Emerging roles in cell cycle progression, apoptosis, and neurogenetic disease
Barker, P. A., & Salehi, A. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10160 · Cited by 320
Tarhini, A. A., Edington, H., Butterfield, L. H., Lin, Y., Shuai, Y., Tawbi, H., Sander, C., Yin, Y., Holtzman, M., Johnson, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087705 · Cited by 310
Valmori, D., Souleimanian, N. E., Tosello, V., Bhardwaj, N., Adams, S., O'Neill, D., Pavlick, A., Escalon, J. B., Cruz, C. M., Angiulli, A., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703395104 · Cited by 299
Weber, J. S., Salgaller, M. L., Samid, D., Johnson, B., Herlyn, M., Lassam, N. J., Treisman, J. S., & Rosenberg, S. A. (1994) · PubMed · Cited by 294
Yegnasubramanian, S., Haffner, M. C., Zhang, Y., Gurel, B., Cornish, T. C., Wu, Z., Irizarry, R. A., Morgan, J., Hicks, J., DeWeese, T. L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6088 · Cited by 294
LAGE-1, a new gene with tumor specificity
Lethé, B., Lucas, S., Michaux, L., Smet, C. D., Godelaine, D., Serrano, A., Plaen, E. D., & Boon, T. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980610)76:6<903::aid-ijc22>3.0.co;2-1 · Cited by 264
Gibney, G. T., Kudchadkar, R. R., DeConti, R. C., Thebeau, M. S., Czupryn, M. P., Tetteh, L., Eysmans, C., Richards, A., Schell, M. J., Fisher, K. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2468 · Cited by 258
Cause and Consequence of Cancer/Testis Antigen Activation in Cancer
Whitehurst, A. W. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140326 · Cited by 250
Odunsi, K. O., Jungbluth, A. A., Stockert, E., Qian, F., Gnjatic, S., Tammela, J., Intengan, M., Beck, A. F., Keitz, B. T., Santiago, D., et al. (2003) · PubMed · Cited by 249
Adams, S., O'Neill, D. W., Nonaka, D., Hardin, E., Chiriboga, L., Siu, K., Cruz, C. M., Angiulli, A., Angiulli, F., Ritter, E., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.1.776 · Cited by 247
Fong, L., Kwek, S. S., O'Brien, S., Kavanagh, B., McNeel, D. G., Weinberg, V., Lin, A. M., Rosenberg, J., Ryan, C. J., Rini, B. I., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3529 · Cited by 246
Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage
Barrow, C., Browning, J., MacGregor, D., Davis, I. D., Sturrock, S., Jungbluth, A. A., & Cebon, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1544 · Cited by 238
Jäger, E., Jäger, D., Karbach, J., Chen, Y.-T., Ritter, G., Nagata, Y., Gnjatic, S., Stockert, E., Arand, M., Old, L. J., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.4.625 · Cited by 229
Jäger, E., Stockert, E., Zidianakis, Z., Chen, Y.-T., Karbach, J., Jäger, D., Arand, M., Ritter, G., Old, L. J., & Knuth, A. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991022)84:5<506::aid-ijc10>3.0.co;2-6 · Cited by 227
Immune targets and neoantigens for cancer immunotherapy and precision medicine
Wang, R.-F., & Wang, H. Y. (2017) · Cell Research · doi:10.1038/cr.2016.155 · Cited by 225
Jäger, E., Karbach, J., Gnjatic, S., Neumann, A., Bender, A., Valmori, D., Ayyoub, M., Ritter, E., Ritter, G., Jäger, D., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606512103 · Cited by 216
Fourcade, J., Sun, Z., Pagliano, O., Chauvin, J.-M., Sander, C., Janjic, B., Tarhini, A. A., Tawbi, H. A., Kirkwood, J. M., Moschos, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2908 · Cited by 209
Jungbluth, A. A., Antonescu, C. R., Busam, K. J., Iversen, K., Kolb, D., Coplan, K., Chen, Y. T., Stockert, E., Ladanyi, M., & Old, L. J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1451 · Cited by 203
Gnjatic, S., Atanackovic, D., Jäger, E., Matsuo, M., Selvakumar, A., Altorki, N. K., Maki, R. G., Dupont, B., Ritter, G., Chen, Y.-T., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1133324100 · Cited by 203
Odunsi, K., Matsuzaki, J., Karbach, J., Neumann, A., Mhawech-Fauceglia, P., Miller, A., Beck, A., Morrison, C. D., Ritter, G., Godoy, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117208109 · Cited by 200
van Rhee, F., Szmania, S. M., Zhan, F., Gupta, S. K., Pomtree, M., Lin, P., Batchu, R. B., Moreno, A., Spagnoli, G., Shaughnessy, J., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3707 · Cited by 194
Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
Odunsi, K., Matsuzaki, J., James, S. R., Mhawech-Fauceglia, P., Tsuji, T., Miller, A., Zhang, W., Akers, S. N., Griffiths, E. A., Miliotto, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0126 · Cited by 193
Zeng, G., Wang, X., Robbins, P. F., Rosenberg, S. A., & Wang, R.-F. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061507398 · Cited by 193
Engell-Noerregaard, L., Hansen, T. H., Andersen, M. H., thor Straten, P., & Svane, I. M. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0568-4 · Cited by 185
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma
Maki, R. G., Jungbluth, A. A., Gnjatic, S., Schwartz, G. K., D’Adamo, D. R., Keohan, M. L., Wagner, M. J., Scheu, K., Chiu, R., Ritter, E., et al. (2013) · Sarcoma · doi:10.1155/2013/168145 · Cited by 179
Nishikawa, H., Jäger, E., Ritter, G., Old, L. J., & Gnjatic, S. (2005) · Blood · doi:10.1182/blood-2005-02-0607 · Cited by 173
Weiser, T. S., Guo, Z. S., Ohnmacht, G. A., Parkhurst, M. L., Tong-On, P., Marincola, F. M., Fischette, M. R., Yu, X., Chen, G. A., Hong, J. A., et al. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200103000-00010 · Cited by 162
PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients
Fourcade, J., Kudela, P., Sun, Z., Shen, H., Land, S. R., Lenzner, D., Guillaume, P., Luescher, I. F., Sander, C., Ferrone, S., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803245 · Cited by 161
Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules
Zeng, G., Touloukian, C. E., Wang, X., Restifo, N. P., Rosenberg, S. A., & Wang, R. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.2.1153 · Cited by 151
Karpf, A. R., Lasek, A. W., Ririe, T. O., Hanks, A. N., Grossman, D., & Jones, D. A. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.1.18 · Cited by 150
Yeast homolog of a cancer‐testis antigen defines a new transcription complex
Kisseleva-Romanova, E., Lopreiato, R., Baudin‐Baillieu, A., Rousselle, J.-C., Ilan, L., Hofmann, K., Namane, A., Mann, C., & Libri, D. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601235 · Cited by 149
Kitano, S., Tsuji, T., Liu, C., Hirschhorn-Cymerman, D., Kyi, C., Mu, Z., Allison, J. P., Gnjatic, S., Yuan, J. D., & Wolchok, J. D. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0068 · Cited by 144
Cronwright, G., Blanc, K. L., Gotherstrom, C. O. T., D’Arcy, P., Ehnman, M., & Brodin, B. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1882 · Cited by 138
Moon, E. K., Ranganathan, R., Eruslanov, E. B., Kim, S., Newick, K., O’Brien, S., Lo, A., Liu, X., Zhao, Y., & Albelda, S. Μ. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1070 · Cited by 127
NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
Zarour, H. M., Storkus, W. J., Brusić, V., Williams, E., & Kirkwood, J. M. (2000) · PubMed · Cited by 127
Pollack, S. M., Jungbluth, A. A., Hoch, B. L., Farrar, E. A., Bleakley, M., Schneider, D. J., Loggers, E. T., Rodler, E. T., Eary, J. F., Conrad, E. U., et al. (2012) · Cancer · doi:10.1002/cncr.27446 · Cited by 126
Weber, J. S., Hamid, O., Chasalow, S. D., Wu, D., Parker, S. M., Galbraith, S. M., Gnjatic, S., & Berman, D. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31823aa41c · Cited by 124
Lai, J.-P., Robbins, P. F., Raffeld, M. A., Aung, P. P., Tsokos, M., Rosenberg, S. A., Miettinen, M., & Lee, C. R. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.31 · Cited by 122
Weide, B., Zelba, H., Derhovanessian, E., Pflugfelder, A., Eigentler, T., Giacomo, A. M. D., Maio, M., Aarntzen, E. H. J. G., de Vries, I. J. M., Sucker, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.2271 · Cited by 118
Kageyama, S., Wada, H., Muro, K., Niwa, Y., Ueda, S., Miyata, H., Takiguchi, S., Sugino, S. H., Miyahara, Y., Ikeda, H., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-246 · Cited by 115
Directions in the immune targeting of cancer: Lessons learned from the cancer‐testis Ag NY‐ESO‐1
Nicholaou, T., Ebert, L. M., Davis, I. D., Robson, N. C., Klein, O., Maraskovsky, E., Chen, W., & Cebon, J. S. (2006) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2006.01446.x · Cited by 113
Immunomic analysis of human sarcoma
Lee, S., Obata, Y., Yoshida, M., Stockert, E., Williamson, B., Jungbluth, A. A., Chen, Y., Old, L. J., & Scanlan, M. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437972100 · Cited by 113
Woloszynska‐Read, A., Mhawech-Fauceglia, P. Y., Yu, J., Odunsi, K. O., & Karpf, A. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5279 · Cited by 110
CT-X antigen expression in human breast cancer
Grigoriadis, A. E., Caballero, O. L., Hoek, K. S., Silva, L. M. D., Chen, Y., Shin, S. J., Jungbluth, A. A., Miller, L. D., Clouston, D. R., Cebon, J. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906840106 · Cited by 109
Tsuji, T., Yasukawa, M., Matsuzaki, J., Ohkuri, T., Chamoto, K., Wakita, D., Azuma, T., Niiya, H., Miyoshi, H., Kuzushima, K., et al. (2005) · Blood · doi:10.1182/blood-2004-09-3663 · Cited by 106
Roszkowski, J. J., Lyons, G. E., Kast, W. M., Yee, C., van Besien, K., & Nishimura, M. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2076 · Cited by 105
Mischo, A., Kubuschok, B., Ertan, K., Preuss, K., Romeike, B. F. M., Regitz, E., Schormann, C., de Bruijn, D. R. H., Wadle, A., Neumann, F., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21352 · Cited by 102
Chen, Y., Chen, Y., Ross, D. S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017876 · Cited by 98
Yuan, J. D., Ginsberg, B., Page, D. B., Li, Y., Rasalan, T. S., Gallardo, H. F., Xu, Y., Adams, S., Bhardwaj, N., BUSAM, K. J., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1011-9 · Cited by 95
Natsume, A., Wakabayashi, T., Tsujimura, K., Shimato, S., Ito, M., Kuzushima, K., Kondo, Y., Sekido, Y., Kawatsura, H., Narita, Y., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23407 · Cited by 93
NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
Ademuyiwa, F. O., Bshara, W., Attwood, K. M., Morrison, C., Edge, S. B., Ambrosone, C. B., O’Connor, T. L., Levine, E. G., Miliotto, A. J., Ritter, E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038783 · Cited by 93
Morris, E. C., Tsallios, A., Bendle, G. M., Xue, S., & Stauss, H. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500357102 · Cited by 92
Zhang, H. H., Mei, M.-H., Fei, R., Liu, F., Wang, J. H., Liao, W., Qin, L. L., Wei, L., & Chen, H. (2010) · Journal of Viral Hepatitis · doi:10.1111/j.1365-2893.2010.01269.x · Cited by 87
Kakimi, K., Isobe, M., Uenaka, A., Wada, H., Sato, E., Doki, Y., Nakajima, J., Seto, Y., Yamatsuji, T., Naomoto, Y., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.25955 · Cited by 84
NY‐ESO‐1 protein expression and humoral immune responses in prostate cancer
Fosså, A., Berner, A., Fosså, S. D., Hernes, E., Gaudernack, G., & Smeland, E. B. (2004) · The Prostate · doi:10.1002/pros.20025 · Cited by 79
Tsuji, T., Sabbatini, P. J., Jungbluth, A. A., Ritter, E., Pan, L. S., Ritter, G., Ferran, L. J., Spriggs, D. R., Salazar, A. Μ., & Gnjatic, S. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0089 · Cited by 77
Held, G., Matsuo, M., Epel, M., Gnjatic, S., Ritter, G., Lee, S. Y., Tai, T. Y., Cohen, C. J., Old, L. J., Pfreundschuh, M. G., et al. (2004) · European Journal of Immunology · doi:10.1002/eji.200425297 · Cited by 76
Ayyoub, M., Taub, R. N., Keohan, M. L., Hesdorffer, M. E., Metthez, G., Memeo, L., MANSUKHANI, M. M., Hibshoosh, H. H., Hesdorffer, C. S., & Valmori, D. (2004) · PubMed · Cited by 75
Sharma, P., Gnjatic, S., Jungbluth, A. A., Williamson, B., Herr, H. W., Stockert, E., Dalbagni, G. M., Donat, S. M., Reuter, V. E., Santiago, D., et al. (2003) · PubMed · Cited by 74
Kim, S., Lee, S., Lee, C. H., Lee, M. K., Kim, Y. D., Shin, D., Choi, K. U., Kim, J. Y., Park, D. Y., & Sol, M. Y. (2009) · Lung · doi:10.1007/s00408-009-9181-3 · Cited by 73
Theurillat, J.-P. P., Ingold, F., Frei, C., Zippelius, A., Varga, Z., Seifert, B., Chen, Y., Jäger, D., Knuth, A. K., & Moch, H. (2007) · International Journal of Cancer · doi:10.1002/ijc.22376 · Cited by 69
Rodolfo, M., Luksch, R., Stockert, E., Chen, Y., Collini, P., Ranzani, T., Lombardo, C., Dalerba, P. D., Rivoltini, L., Arienti, F., et al. (2003) · PubMed · Cited by 67
Ebert, L. M., MacRaild, S., Zanker, D. J., Davis, I. D., Cebon, J. S., & Chen, W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048424 · Cited by 67
Pollack, S. M., Lu, H., Gnjatic, S., Somaiah, N., O'Malley, R. B., Jones, R. L., Hsu, F. J., & ter Meulen, J. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000183 · Cited by 65
Li, B., Zhu, X., Sun, L., Li, Y., Zhang, J., Li, H., & Ye, Z. (2014) · Oncotarget · doi:10.18632/oncotarget.2505 · Cited by 62
Smith, H. A., Cronk, R. J., Lang, J. M., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2127 · Cited by 62
Pollack, S. M., Li, Y., Blaisdell, M. J., Farrar, E. A., Chou, J., Hoch, B. L., Loggers, E. T., Rodler, E. T., Eary, J. F., Conrad, E. U., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032165 · Cited by 61
SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer
Dhodapkar, K. M., Gettinger, S. N., Das, R., Zebroski, H. A., & Dhodapkar, M. V. (2013) · OncoImmunology · doi:10.4161/onci.25205 · Cited by 60
Gal, F. L., Ayyoub, M., Dutoit, V., Widmer, V., Jäger, E., Cerottini, J., Dietrich, P., & Valmori, D. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000161398.34701.26 · Cited by 59
Hemminger, J. A., Toland, A. E., Scharschmidt, T. J., Mayerson, J. L., Kraybill, W. G., D, D. C. G., & Iwenofu, O. H. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.133 · Cited by 56
Cancer-testis (CT) antigen expression in medulloblastoma
Oba‐Shinjo, S. M., Caballero, O. L., Jungbluth, A. A., Rosemberg, S., Old, L. J., Simpson, A. J. G., & Marie, S. K. N. (2008) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · doi:10.13140/rg.2.2.16107.57126 · Cited by 56
Sharma, M. D., Shinde, R. S., McGaha, T. L., Huang, L., Holmgaard, R., Wolchok, J. D., Mautino, M. R., Celis, E., Sharpe, A. H., Francisco, L., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-o19 · Cited by 56
Epigenetic Modulation to Enable Antigen-specific T-cell Therapy of Colorectal Cancer
Chou, J., Voong, L. N., Mortales, C., Towlerton, A. M. H., Pollack, S. M., Chen, X., Yee, C., Robbins, P. F., & Warren, E. H. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31824300c7 · Cited by 55
Yang, Z., Chevolot, Y., Géhin, T., Solassol, J., Mangé, A., Souteyrand, É., & Laurenceau, E. (2012) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2012.08.019 · Cited by 52
Ray, S., Chhabra, A., Chakraborty, N. G., Hegde, U. P., Dorsky, D. I., Chodon, T., von Euw, E., Comin-Anduix, B., Koya, R. C., Ribas, A., et al. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.04.013 · Cited by 51
Xue, S., Gao, L., Ahmadi, M., Ghorashian, S., Barros, R. D. M., Pospori, C., Holler, A., Wright, G. P., Thomas, S., Topp, M. S., et al. (2012) · OncoImmunology · doi:10.4161/onci.22590 · Cited by 51
Roles of cancer/testis antigens (CTAs) in breast cancer
Li, Y., Li, J., Wang, Y., Zhang, Y., Chu, J., Sun, C., Fu, Z., Huang, Y., Zhang, H., Yuan, H., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.02.031 · Cited by 51
Dubovsky, J. A., & McNeel, D. G. (2007) · The Prostate · doi:10.1002/pros.20665 · Cited by 50
Chhabra, A., Yang, L., Wang, P., Comín-Anduix, B., Das, R., Chakraborty, N. G., Ray, S., Mehrotra, S., Yang, H., Hardee, C. L., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.2.1063 · Cited by 49
Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6).
Cho, H. J., Caballero, O. L., Gnjatic, S., Andrade, V. C. C., Colleoni, G. W. B., Vettore, A. L., Outtz, H. H., Fortunato, S. R., Altorki, N. K., Ferrera, C. A., et al. (2006) · PubMed · Cited by 49
NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer
Akçakanat, A., Kanda, T., Koyama, Y., Watanabe, M., Kimura, E., Yoshida, Y., Komukai, S., Nakagawa, S., Odani, S., Fujii, H., et al. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0768-3 · Cited by 46
Toor, A. A., Payne, K. K., Chung, H. M., Sabo, R., Hazlett, A. F., Kmieciak, M., Sanford, K., Williams, D. C., Clark, W., Roberts, C. H., et al. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09225.x · Cited by 46
Klar, A. S., Gopinadh, J., Kleber, S., Wadle, A., & Renner, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139221 · Cited by 44
Fourcade, J. J., Sun, Z., Kudela, P., Janjic, B. M., Kirkwood, J. M., El-Hafnawy, T., & Zarour, H. M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903612 · Cited by 40
Cruz, L. J., Rueda, F., Simón‐Gracia, L., Cordobilla, B., Alberício, F., & Domingo, J. C. (2013) · Nanomedicine · doi:10.2217/nnm.13.66 · Cited by 40
Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer.
Wang, Y., Wu, X., Zhao, A., Yuan, Y., Chen, Y., Jungbluth, A. A., Gnjatic, S., Santiago, D., Ritter, G., Chen, W., et al. (2004) · PubMed · Cited by 40
New York Esophageal Squamous Cell Carcinoma-1 and Cancer Immunotherapy
Esfandiary, A., & Ghafouri‐Fard, S. (2015) · Immunotherapy · doi:10.2217/imt.15.3 · Cited by 38
Enhanced expression of cancer testis antigen genes in glioma stem cells
Yawata, T., Nakai, E., Park, K. C., Chihara, T., Kumazawa, A., Toyonaga, S., Masahira, T., Nakabayashi, H., Kaji, T., & Shimizu, K. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20614 · Cited by 37
Tan, M. P., Dolton, G. M., Gerry, A. B., et al. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12828 · Cited by 33
Perez, D. R., Hauswirth, F., Jäger, D., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25836 · Cited by 32
Sioud, M., Nyakas, M., Sæbøe‐Larssen, S., Mobergslien, A., Aamdal, S., & Kvalheim, G. (2016) · Case Reports in Medicine · doi:10.1155/2016/9639585 · Cited by 31
A Potential Role for Immunotherapy in Thyroid Cancer by Enhancing NY-ESO-1 Cancer Antigen Expression
Gunda, V., Frederick, D. T., Bernasconi, M. J., Wargo, J. A., & Parangi, S. (2014) · Thyroid · doi:10.1089/thy.2013.0680 · Cited by 30
Woods, K., Knights, A. J., Anaka, M., Schittenhelm, R. B., Purcell, A. W., Behren, A., & Cebon, J. S. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0111-7 · Cited by 29
High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer
Tanja, B. Č., Spagnoli, G. C., Juretić, A., Jakić‐Razumović, J., Podolski, P., & Šarić, N. (2011) · Medical Oncology · doi:10.1007/s12032-011-0120-9 · Cited by 29
dos Santos, L. I., Galvão-Filho, B., de Faria, P. C., Junqueira, C., Dutra, M. S., Teixeira, S. M. R., Rodrigues, M. M., Ritter, G., Bannard, O., Fearon, D. T., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1634-8 · Cited by 23
Goff, S. L., Robbins, P. F., El‐Gamil, M., & Rosenberg, S. A. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181affbf0 · Cited by 21
MicroRNA-874 Functions as a Tumor Suppressor by Targeting Cancer/Testis Antigen HCA587/MAGE-C2
Song, X., Song, W., Wang, Y., Wang, J., Li, Y., Qian, X., Pang, X., Zhang, Y., & Yin, Y. (2016) · Journal of Cancer · doi:10.7150/jca.13674 · Cited by 21
Luetkens, T., Kobold, S., Cao, Y., Ristic, M., Schilling, G., Tams, S., Bartels, B. M., Templin, J., Bartels, K., Hildebrandt, Y., et al. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1588-x · Cited by 20
Li, M., Shi, H., Mu, Y., Luo, Z., Zhang, H., Wan, Y., Zhang, D., Lu, L., Men, K., Tian, Y., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-179 · Cited by 20
Chawla, S. P., Tine, B. A. V., Pollack, S. M., Ganjoo, K. N., ELIAS, A. D., Riedel, R. F., Attia, S., Choy, E., Okuno, S. H., Agulnik, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx387.007 · Cited by 13
Cited by
Martinez, M., & Moon, E. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00128 · Cited by 851
Cancer vaccines: the next immunotherapy frontier
Lin, M. J., Svensson-Arvelund, J., Lubitz, G. S., Marabelle, A., Melero, I., Brown, B. D., & Brody, J. D. (2022) · Nature Cancer · doi:10.1038/s43018-022-00418-6 · Cited by 843
The future of cancer immunotherapy: microenvironment-targeting combinations
Murciano-Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 749
Beyond immune checkpoint blockade: emerging immunological strategies
Kubli, S. P., Berger, T., Araujo, D. V., Siu, L. L., & Mak, T. W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00155-y · Cited by 461
Immunotherapy in breast cancer: an overview of current strategies and perspectives
Debien, V., De Caluwé, A., Wang, X., Piccart-Gebhart, M., Tuohy, V. K., Romano, E., & Buisseret, L. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00508-3 · Cited by 368
Metadata
- Authors
- Thomas, R., Al-Khadairi, G., Roelands, J., Hendrickx, W., Dermime, S., Bedognetti, D., & Decock, J.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2018-05-01
- Volume
- 9
- Pages
- 947-947
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W2802528628
- Cited by
- 393
- References
- 137
- FWCI
- 12.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.